IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with NSCLC, SCLC, GC/GEJC, uHCC, BTC, MIBC and advanced or recurrent dMMR.

Get your questions about IMFINZI answered Here are answers to some questions about IMFINZI and unresectable Stage 3 non-small cell lung cancer (NSCLC). Remember, your doctor is the best …

IMFINZI is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat adults with a type of uterine cancer called endometrial cancer that has spread …

IMFINZI is the #1 prescribed immunotherapy* for adults with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed following chemotherapy and radiation given …

Find out about the FDA Breakthrough Therapy designation to IMFINZI for Limited-Stage and previously untreated Extensive-Stage Small Cell Lung Cancer.

Before IMFINZI was approved in 2018, there were only limited advancements to the current standard of care for unresectable Stage 3 NSCLC. If CRT has worked for you, IMFINZI may be your next step.

IMFINZI is the first and only immunotherapy approved for both limited-stage and extensive-stage small cell lung cancer (SCLC) IMFINZI can help treat limited-stage small cell lung cancer that has not …

Learn about IMFINZI® (durvalumab) as a combination immunotherapy with IMJUDO® (tremelimumab-actl) to treat adults diagnosed with unresectable hepatocellular carcinoma (uHCC).

Find the clinical trial results for IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) with chemotherapy, a treatment for adults diagnosed with stage 4 non-small cell lung cancer (NSCLC).

Learn how long IMFINZI treatment lasts and what to expect during therapy for unresectable Stage 3 non-small cell lung cancer (NSCLC).